ERBB2 and breast carcinoma: Independently of the unconfirmed and possibly low, correlation between the rs12976445 variant and breast cancer risk, an awareness of miR-SNPs in the patient genome may allow oncologists to predict whether the patient is likely to respond to anti-HER2 chemotherapeutic drugs (17).